



Atty. Docket No.: 8912/2015

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Seery, et al.
Serial No.: 10/781,581
Filed: February 18, 2004
Entitled: Apoptosis-Related Kinase/GPCRs

Examiner: Not yet assigned
Group Art Unit: Not yet assigned
Conf. No.: Not yet assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Mary Wilson

Name of Person Mailing Paper

Mary
Signature of Person Mailing Paper

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449;
3. Copies of Cited References; and
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 8912/2015. A duplicate of this transmittal letter is enclosed for this purpose.


Respectfully submitted,

Date: 5/27/04

Mark J. Fitzgerald
Name: Mark J. Fitzgerald
Registration No.: 45,928
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100

Atty. Docket No.: 8912/2015 **PATENT**
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Seery, et al.	Examiner:	Not yet assigned
Serial No.:	10/781,581	Group Art Unit:	Not yet assigned
Filed:	February 18, 2004	Conf. No.:	Not yet assigned
Entitled:	Apoptosis-Related Kinase/GPCRs		



CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Mary Wilson
Name of Person Mailing Paper


Signature of Person Mailing Paper

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list.

Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,

Date: 5/27/04


Name: Mark J. Fitzgerald
Registration No.: 45,928
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No.		Serial No.	
				8912/2015		10/781,581	
				Applicant(s): Seery, et al.			
				Filing Date: February 18, 2004			Group: Not yet assigned
INFORMATION DISCLOSURE STATEMENT							
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation
							YES
	1.	WO02/04657A2	January 17, 2002	WO	C12Q	1/00	X
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
	2.	Lamb, et al., "Oxidative damage to proteins of bronchoalveolar lavage fluid in patients with acute respiratory distress syndrome: Evidence for neutrophil-mediated hydroxylation, nitration, and chlorination", Critical Care Medicine, Sept 27, 1999, V. 9, pages 1738-1744.					
	3.	Gorman, et al., "Oxidative stress and apoptosis in neurodegeneration", Journal of Neurological Sciences (1996), V. 139, pages 45-52.					
	4.	Lotem, et al., "Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β 1 and cancer chemotherapy compounds in myeloid leukemic cells", Blood (1992), V. 80, pages 1750-1757.					
	5.	Naccache, et al., "Granulocyte-Macrophage Colony-Stimulating factor modulates the Excitation-Response coupling sequence in human neutrophils", Journal of Immunology (1988), V. 140, pages 3541-3545.					
	6.	Weisbart, et al., "Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator", Nature (1985), V. 314, pages 361-363.					
	7.	Lopez, et al., "Recombinant human Granulocyte-Macrophage Colony-stimulating factor stimulates in Vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival", Journal of Clinical Investigations (1986), V. 78, pages 1220-1228.					
	8.	Yasui, et al., "Granulocyte macrophage-colony stimulating factor delays neutrophil apoptosis and primes its function through la-type phosphoinositide 3-kinase", Journal of Leukocyte Biology, November 2002, V. 72, pages 1020-1026.					
	9.	Hirsch, et al., "Central role for G Protein-Coupled phosphoinositide 3-Kinase γ in inflammation", Science (2000), V. 287, pages 1049-1053.					
	10.	DiPersio, et al., "Human granulocyte-macrophage colony-stimulating factor and other cytokines prime human neutrophils for enhanced arachidonic acid release and leukotriene B_4 synthesis", Journal of Immunology (1998), V. 140, pages 4315-4322.					



	11.	Klein, et al., "Granulocyte-macrophage colony-stimulating factor delays neutrophil constitutive apoptosis through phosphoinositide 3-kinase and extracellular signal-regulated kinase pathways", Journal of Immunology (2000), V. 164, pages 4286-4291.
	12.	Helgason, et al., "Targeted disruption of <i>SHIP</i> leads to hemopoietic perturbations, lung pathology, and a shortened life span", Genes and Development (1998), V. 12, pages 1610-1620.
	13.	Cadwallader, et al., "Regulation of phosphatidylinositol 3-kinase activity and phosphatidylinositol 3, 4, 5-trisphosphate accumulation by neutrophil priming agents", Journal of Immunology (2002), V. 169, pages 3336-3344.
	14.	Al-Shami, et al., "Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. I. Tyrosine phosphorylation-dependent stimulation of phosphatidylinositol 3-kinase and inhibition by phorbol esters", Blood (1997), V. 89, pages 1035-1044.
	15.	Noguera, et al., "Enhanced neutrophil response in chronic obstructive pulmonary disease", Thorax (2001), V. 56, pages 432-437.
	16.	Matute-Bello, et al., "Neutrophil apoptosis in the acute respiratory distress syndrome", American Journal of Critical Care Medicine (1997), V. 156, pages 1969-1977.
*	17.	Mori, et al., "Involvement of fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelosuppression", Blood (1998), V. 92, pages 101-107.
?	18.	Lotem, et al., "Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β 1 and cancer chemotherapy compounds in myeloid leukemic cells", Blood (1992), V. 80, pages 1750-1757.
EXAMINER		DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.